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Abstract
Intrauterine and postnatal longitudinal growth is controlled by a strong genetic component that regulates a complex
network of endocrine factors integrating them with cellular proliferation, differentiation and apoptotic processes in target
tissues, particularly the growth centers of the long bones. Here we report on a patient born small for gestational age (SGA)
with severe, proportionate postnatal growth retardation, discreet signs of skeletal dysplasia, microcephaly and moyamoya
disease. Initial genetic evaluation revealed a novel heterozygous IGF1R p.Leu1361Arg mutation affecting a highly conserved
residue with the insulin-like growth factor type 1 receptor suggestive for a disturbance within the somatotropic axis.
However, because the mutation did not co-segregate with the phenotype and functional characterization did not reveal an
obvious impairment of the ligand depending major IGF1R signaling capabilities a second-site mutation was assumed.
Mutational screening of components of the somatotropic axis, constituents of the IGF signaling system and factors involved
in cellular proliferation, which are described or suggested to provoke syndromic dwarfism phenotypes, was performed. Two
compound heterozygous PCNT mutations (p.[Arg585X];[Glu1774X]) were identified leading to the specification of the
diagnosis to MOPD II. These investigations underline the need for careful assessment of all available information to derive a
firm diagnosis from a sequence aberration.
Citation: Mu ¨ller E, Dunstheimer D, Klammt J, Friebe D, Kiess W, et al. (2012) Clinical and Functional Characterization of a Patient Carrying a Compound
Heterozygous Pericentrin Mutation and a Heterozygous IGF1 Receptor Mutation. PLoS ONE 7(5): e38220. doi:10.1371/journal.pone.0038220
Editor: Hironori Waki, Graduate School of Medicine, the University of Tokyo, Japan
Received December 10, 2011; Accepted May 1, 2012; Published May 31, 2012
Copyright:  2012 Mu ¨ller et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: WK has received research grants from Pfizer, Novo Nordisk, Sandoz, Ipsen and Merck Serono. RP has received research grants from Eli Lilly and Merck
Serono and serves on an Ipsen advisory board. This work is supported by grants of the Medical Faculty of the University of Leipzig (to EM) and the Deutsche
Forschungsgemeinschaft (Bonn, Germany; project PF 225/3 to J. Klammt, WK, and RP). WK is also supported by the LIFE program of the Medical Faculty, University
of Leipzig, the IFB Adiposity Diseases, BMBF and Deutsche Forschungsgemeinschaft (KFO 152). PHH, J. Kratzsch, DD, TK, TW, DF, and SL have nothing to disclose.
Competing Interests: WK has received research grants from Pfizer, Novo Nordisk, Ipsen and Merck Serono. RP has received research grants from Eli Lilly and
Merck Serono and serves on an Ipsen advisory board. PHH, J. Kratzsch, J. Klammt, DD, EM, TK, TW, DF, and SL have nothing to disclose. This does not alter the
authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: Wieland.Kiess@medizin.uni-leipzig.de
. These authors contributed equally to this work.
Introduction
The process of human growth is an extraordinarily complex
system with the somatotropic GH-IGF1 axis in the center of the
endocrine regulation of pre- and postnatal growth. Both micro-
cephalic osteodysplastic primordal dwarfism type II (type Ma-
jewski or MOPD II, MIM 210720) [1,2] and mutations in the
insulin-like growth factor 1 receptor gene (IGF1R, MIM 270450)
are very rare causes of pre- and postnatal growth retardation.
Starting in 2008 it was discovered that biallelic mutations in the
pericentrin gene (PCNT) cause MOPD II. Absence of functional
PCNT results in disorganized mitotic spindles and missegregation
of chromosomes [3]. Mutations in the IGF1R gene can result in
intrauterine growth retardation (IUGR) without postnatal catch
up growth. Aberrant IGF1R expression or protein structure are
described to lead to IGF1R haploinsufficiency [4,5], disturbed
processing of the proreceptor [6,7], decreased ligand binding [8],
abrogated IGF1R tyrosine kinase activity and reduced receptor
autophosphorylation [9–11]. Here we report on a female patient
with IUGR and severe postnatal growth failure carrying a novel
IGF1R mutation and a compound heterozygous mutation in the
PCNT gene. Additional phenotypic signs were microcephaly,
mircodontia, clinodactyly, retarded bone age, and skeletal
abnormalities. Due to the initial assumption of an endocrine
disturbance underlying the severe growth restriction comprehen-
sive endocrine evaluation was performed but did not reveal any
profound abnormalities. To assess the contribution of the IGF1R
mutation to the phenotype of the patient in vitro studies examining
the molecular consequences of the IGF1R mutation were
performed.
Results
Patient characteristics and genetic analysis
2The female patient was born with IUGR (height 31.0 cm,
-2.0 SDS; weight 680 g, -1.7 SDS corrected for gestational age;
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e38220HC 21.5, ,3
rd percentile) after 29 weeks and 6 days of pregnancy
as the child of non-consanguineous, Caucasian, healthy parents.
The patient’s father is of normal height (179.4 cm, -0.256 height-
SDS), but her mother was also born small for gestational age
(height 47 cm, -1.94 height-SDS; weight 2400 g, -1.9 weight-SDS)
and has a final height of 157 cm (-1.75 height-SDS) (Fig. 1A). The
patient showed no catch-up growth (age 4.8 yr; height 71.2 cm, -
8.1 SDS; weight 5.6 kg, -13.1 SDS; BMI 11.0 kg/m
2, -4.3 SDS;
HC 39.4 cm, -7.4 SDS) (Fig. 1A and 1B) after birth nor under
GH treatment (37,5-69 ug/kg/d) over a period of 27 months. GH
has been initiated at the age of 2.5 yr and ended at the age of
4.75 yr because of failure to accelerate growth velocity. Basal GH
(0.8 ng/ml) measured at the age of 2.5 yr and GH release
stimulated by arginine provocation test (15.8 ng/ml) performed at
1.5 yr showed normal GH secretion. In the course of GH therapy
IGF1 serum levels rose steadily from less than -1.9 SDS at several
occasions before treatment to 1.1 SDS during GH treatment. A
detailed clinical course of the IGF1 serum levels under GH
treatment is provided as supplemental material, published as
supplemental data on the PLoS ONE website at http://ww.
plosone.org (Fig. S1). An IGF1 generation test performed at the
age of 2.5 years, though, did not result in a substantial increase of
IGF1 serum levels (0.15 mg rhGH daily sc; one week IGF1 change
from 73 ng/ml to 79 ng/ml). Postnatal growth retardation as well
as microcephaly of the girl were profound, but did not worsen over
time (Fig. 1C). On clinical examination she showed dispropor-
tionate shortness of forearms and legs, bilateral clinodactyly V,
significant facial asymmetry and hypoplasia of the teeth (Fig. 1B
and 1D). Radiological skeletal examinations at the age of 4.1 and
5.7 years revealed severely retarded bone age (Fig. 2A) and the
radiological features of skeletal dysplasia as been described in
MOPD II like V-shaped flare of the distal femoral metaphyses
with corresponding triangular shape of the distal femoral epiphyses
(Fig. 2B). The pelvis was high and small and showed the typical
coxa vara (Fig. 2C) [1,2].
At the age of 5.7 years she presented with clinical signs of
cerebral ischemia like numbness in her right arm and hand.
Neuroimaging revealed severe cerebral vascular anomalies classi-
fied as moyamoya disease without aneurysms (Fig. 2D). In
addition old infarcts in the right white matter region could be
identified (Fig. 2E). Surgical revascularization by encephalomyo-
synangiosis and encephalodurosynangiosis was performed at the
age of 5.9 on the left side and at the age of 6.2 years on the other
side to protect against future stroke-like episodes. In addition the
patient received an antiplatelet medication. Because she was an
acetylsalicyl acid-non-responder the treatment was successfully
continued with clopidogrel.
Because of a mild speech delay speech therapy was started
between the age of 2 and 3 years. At the age of 7.1 years
neuropsychological testing was performed with the Kaufmann
Assesment Battery for Children (K-ABC, 2
nd edition). The results
were more than 2 SD below the mean and spoke in favour of
mental retardation.
Since many patients with MOPD II show a high frequency of
insulin resistance and diabetes mellitus glucose metabolism was
investigated at the age of 7.1 and 7.5 years [3,12]. Fasting blood
glucose was 60 and 70 mg/dl, respectively (normal range:
,110 mg/dl) and fasting serum insulin was ,2 mU/l (normal
range: ,2 to 10 mU/l). During an oral glucose tolerance test
(1.75 g/kg body weight=11 g/patient) blood glucose increased
from 60 to 71 mg/dl at 120 min (normal reference range:
,140 mg/dl) and excluded glucose intolerance at the age of 7.1
years. TSH, free T3, free T4, parathormone, aspartate amino-
transferase, alanine aminotransferase, alkaline phosphatase, ferri-
tin, vitamin B12 and folic acid were within the normal range.
Neonatal screening for metabolic and endocrine diseases was
normal.
The karyotype of the patient was normal (46,XX). Because no
precise diagnosis could be obtained from clinical examination
molecular genetic testing was performed. dHPLC screening of all
coding exons of the IGF1R gene and subsequent direct sequencing
revealed a novel heterozygous nucleotide transversion from
thymine to guanine in exon 21 (c.4082T.G). This mutation
leads to an amino acid exchange from leucine to arginine in
position 1361 of the IGF1R protein (incl. signal peptide;
p.L1361R). Subsequently, all coding exons of the IGF1R gene
were analyzed and no further sequence aberration was detected.
Sequence analysis of exon 21 of 50 unaffected individuals did not
show any sequence aberration at position 4082. The non-
conservative amino acid substitution affects a residue that is
highly conserved among different species (Tab. 1) and is predicted
to be probably damaging (PolyPhen v2; http://genetics.bwh.
harvard.edu/pph2/). The patient’s father was identified as carrier
of the IGF1R-L1361R mutation, whereas exon 21 of the mother
was normal. So far, IGF1R mutations are described to be
inherited in a dominant way. Due to the apparent lack of co-
segregation of the mutant IGF1R-L1361R allele with the growth
retarded phenotype and the in vitro data presented below, the
existence of a second-site mutation was hypothesized, which alone
or in interplay with the IGF1R mutation might cause the
extraordinary phenotype of the patient. Genetic analysis of other
candidate genes including those of the somatotropic axis [IGF1,
growth hormone (GH1), GH receptor (GHR), GH releasing
hormone (GHRH), and GHRH receptor (GHRHR)], and genes
of the IGF1R signaling system [insulin receptor (INSR), insulin
receptor substrate 1 (IRS1) and GAIP C-terminus-interacting
protein 1, synectin (GIPC1)] yielded no conspicuous findings.
Sequencing of the STAT5B gene identified a heterozygous
polymorphism 38bp upstream of exon 6 but was assumed to be
not related to the clinical manifestations of the patient. DNA
diagnostics excluded uniparental disomy of chromosome 14
[upd(14)mat) [13], chromosome 2 and 16 (upd(2)mat; upd(16)mat
[14]], and chromosome 7 (Silver-Russell syndrome, MIM
180860). Analysis of chromosome 15 showed a normal methyla-
tion pattern and no suspicion of Prader-Willi syndrome (MIM
176270).
However, two heterozygous mutations in the PCNT gene
[c.1753C.T (p.R585X) and c.5320G.T (p.E1774X)] were
identified. These mutations lead to premature stop codons like
in other patients with MOPD II [3,15]. The mother was
heterozygous carrier for the c.5320G.T nonsense mutation and
the father heterozygous carrier for the c.1753C.T nonsense
mutation confirming compound heterozygosity in the affected
patient. Consequently, the diagnosis has been specified to MOPD
II, which is described to be a genetically homogeneous condition
due to loss-of-function of PCNT [15].
Cell surface expression and IGF1 induced
phosphorylation of IGF1R, Akt and Mapk/Erk
Although the IGF1R-L1361R mutation does not map to major
structural domains within the receptor known to be involved in
IGF1 ligand binding or kinase activity, we analyzed the signal
transduction capabilities of the mutant receptor with respect to
IGF1 induced receptor autophosphorylation and activation of
major downstream signaling molecules.
Stimulation of the patient’s and wild type fibroblasts with
13 nM IGF1 resulted in a comparable phosphorylation of the
IGF1R in both fibroblast cultures, while incubation without IGF1
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blotting of unphosphorylated IGF1R revealed equal expression of
the IGF1R in mutant and control cells. Moreover, undisturbed
receptor expression at the cell surface was confirmed by flow
cytometry. See supplemental material on PLoS ONE Online
website at http://www.plosone.org (Fig. S2). To investigate the
dose and time dependent effects of IGF1 on the activation of the
mutant receptor without masking by the endogenous wild type
allele, we then determined IGF1 induced IGF1R phosphorylation
and activation of its downstream targets Akt and Mapk/Erk in R
2
cells transfected with IGF1R-WT, IGF1R-L1361R and pcDNA3+
(vector control). Phosphorylation was analyzed at different time
points and different concentrations of IGF1 as outlined in
Materials and Methods. IGF1R-WT and IGF1R-L1361R trans-
fected R
2 cells revealed a time dependent increase in the
phosphorylation of the b-subunit of IGF1R, and the Akt and
Mapk/Erk downstream effectors in the presence of IGF1 (Fig. 3A).
Also, we detected a dose dependent activation of IGF1R, Akt and
Erk (data not shown). However, neither receptor autophosphory-
lation nor downstream signaling was found to be different in
IGF1R-WT and IGF1R-L1361R transfected R
2 cells.
Thus, the heterozygous mutation at the carboxy-terminus of the
IGF1R appears not to affect the IGF1 induced downstream
signaling of the two tested major IGF1R pathways (Fig. 3A).
Protein-protein interaction of the mutant IGF1R with
adapter proteins
The IGF1R binds several adapter proteins at different docking
sites, of which some are located within the C-terminal tail of the
receptor and, thus, reside near to our identified mutation. Some of
these interacting molecules (14-3-3b, GIPC) are involved in
IGF1R signal transduction without directly affecting the previ-
ously analyzed MAPK and AKT pathways. Therefore, we
investigated whether the L1361R mutation affects protein-protein
interactions and quantified them in a yeast two-hybrid system
(Fig. 3B).
Co-transformation of yeast cells with wild type IGF1R-C and
IRS1, p85PI3-K, 14-3-3b, or GIPC resulted in a rapid blue
staining after incubation with X-Gal. The IGF1R-C-K1003A
mutant does not exhibit kinase activity and therefore kinase
dependent interactions of IRS1, p85PI3, 14-3-3ß are abolished.
Interaction with GIPC has been shown to be kinase independent
[16]. As expected, using this negative control lift-off assays of
IRS1, p85PI3-K and 14-3-3ß yielded no ß-galactosidase activity of
yeast colonies. In contrast, interaction of IGF1R-C-K1003A with
GIPC was unaffected and resulted in blue color formation. Lift-off
filter assays of mutant IGF1R-C-L1361R confirmed b-galactosi-
dase reporter gene activation for all tested adapter proteins by
detection of blue stained colonies. To verify and quantify two-
Figure 1. Clinical data of the patient. A, Growth and weight charts of the patient. On the growth chart solid lines indicate 97th, 50th and 3rd
percentiles; the shaded green area exhibits target height calculated from parent’s height (blue triangle, father’s height; red square, mother’s height);
red bar assigns period of rhGH therapy; grey squares mark the corrected age for preterm infants. B, Photograph of the patient at the age of 5.7 yrs. in
comparison to a 5.8 yrs. old boy. C, Head circumference (HC) chart of the patient; 97th, 50th and 3rd percentiles are indicated as black solid lines,
white circles mark the corrected age for preterm infants. D, Photograph of the patient’s hypoplastic teeth.
doi:10.1371/journal.pone.0038220.g001
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activity using ONPG as substrate were performed. The ability of
the positive control IRS1 to associate with IGF1R-C-L1361R was
moderately but significantly increased compared to wild type
IGF1R-C. Co-transformation of IGF1R-C-L1361R with 14-3-3ß
demonstrated a modest decrease in reporter activation. Interaction
Figure 2. Radiological examinations and neuroimaging. A, Left hand at the age of 4.1 years: mild metaphyseal flaring of distal radius and ulna;
shortening of the distal ulna; short metacarpal I; pseudoepiphyses of metacarpals II and V, shortness of the middle and distal phalanges; clinodactyly
of the little finger, bone age was retarded (11 months). B, Left knee at the age of 5.7 years: V-shaped flare of the distal femoral metaphyses; triangular
shape of the distal femoral epiphyses. C, Hip at the age of 5.7 years: high and narrow pelvis with broad cranial parts of the ischia; irregular
metaphyses of the proximal femur; coxa vara. D, Brain MRI at the age of 5.9 years: bilateral occlusion of the intracranial internal carotid artery and the
middle cerebral arteries and occlusion of the right anterior cerebral artery, prominent moyamoya collaterals; E, Brain MRI at the age of 5.7 years: old
infarcts in the right white matter region.
doi:10.1371/journal.pone.0038220.g002
Table 1. Sequence comparison of the IGF1R carboxyl terminus among different species.
1330 1340 1350 1360
|| | |
IGF1R human (patient)* GPGVLVLRAS FDERQPYAHM NGGRKNERALP R RPQSSTC
IGF1R human (wild type) GPGVLVLRAS FDERQPYAHM NGGRKNERALP LPQSSTC
IGF1R mouse GPGVLVLRAS FDERQPYAHM NGGRANERALP LPQSSTC
IGF1R bovine GPGVLVLRAS FDERQPYAHM NGGRKNERALP LPQSSTC
IGF1R X.laevis GPGVVVLRAS FDERQPYAHM NGGRKNERALP LPQSSAC
Consensus GPGVLVLRAS FDERQPYAHM NGGRKNERALP LPQSSTC
*) amino acid numbering according to human UniProtKB acc. P08069; position of the patient’s mutation is marked in bold.
doi:10.1371/journal.pone.0038220.t001
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wild type IGF1R-C. Contrary, GIPC, which has been reported to
interact specifically with the COOH-terminal amino acid 1357–
1367 of the IGF1R but not the insulin receptor [16], demonstrated
an approximately 50% decrease in interaction with the IGF1R-C-
L1361R.
Proliferation of patient’s fibroblasts
We next investigated the proliferation capacity of the patient’s
fibroblasts compared to wild type fibroblasts. We found no
difference in proliferation rate between wild type and patient’s
fibroblasts within 24 h in normal culture medium, serum free
medium and serum free medium supplemented with IGF1. After
additional 24 h incubation the wild type fibroblasts proliferated
significantly in normal culture medium and serum free medium
supplemented with IGF1. In contrast, we detected no further
proliferation of the patient’s fibroblasts after additional 24 h
incubation. Hence, patient fibroblasts exhibited a significantly
decreased cell proliferation capacity despite an early response to
IGF1 (Fig. 4).
Discussion
Herein we report a preterm girl with IUGR, primordial
dwarfism, microcephaly, discreet skeletal dysplasia, and mild
facial dysmorphism during the newborn period and infancy.
Figure 3. IGF1 induced IGF1R phosphorylation and downstream signaling. A, Wild type and L1361R mutant IGF1R autophosphorylation in
transiently transfected R
2 cells after stimulation with 10 nM IGF1 for 0–30 minutes. Immunoblots were incubated with specific antibodies against
phosphorylated IGF1R b-subunit (P-IGF1R), Akt (P-Akt) or Mapk/Erk (P-Mapk/Erk), stripped and subsequently incubated with specific antibodies
against the IGF1R a-subunit (IGF1R), Akt (Akt), or Mapk/Erk (Mapk/Erk). IGF1R a-subunit levels were assessed as control of successful transfection.
Densitometric units were normalized to total levels of IGF1R a-subunit and the fold increase was calculated (IGF1R-WT at 0 min was set 1). Results are
shown as means 6 SEM calculated from four independent experiments. B, Yeast two-hybrid analysis of the interaction of the IGF1R derivatives
(IGF1R-C-WT, IGF1R-C-L1361R, IGF1R-C-KD) with adapter proteins (IRS1, 14-3-3ß, GIPC, PI3Kp85) by lift-off assay (left panel). Positive interactions led to
blue staining (here black) of the colonies. POS, positive control p53 x large T-antigen; NEG, negative control Lamin x large T-antigen. The filter assays
shown are representative for more than three independent experiments. Quantification of protein-protein interaction was measured using ONPG-
assays and data are shown as mean 6 SEM (right panel).
doi:10.1371/journal.pone.0038220.g003
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insufficiency or GH insensitivity, however, IGF1 was low. Owing
to the unclear etiology of the patient’s condition a comprehensive
genetic evaluation was initiated. Analysis of the IGF1R gene
revealed a novel heterozygous variation (p.Leu1361Arg) that was
subjected to further molecular characterization to assess its
biochemical properties and cell-physiological effects. However,
due to the incomplete compatibility of the identified IGF1R
variant with the established features of IGF1R mutation triggered
IGF1 resistance (foremost the lack of co-segregation of the usually
dominantly inherited growth restriction with the IGF1R mutation)
genetic testing of additional candidate genes was continued. The
rationale behind these efforts was to evaluate the possibility of the
co-existence of defects in two or more functionally interacting
proteins that do not follow obvious Mendelian inheritance
patterns. Such oligo- or digenic action of interacting alleles of
distinct genes becomes – if mutated – increasingly recognized as a
mode of disease transmission in the continuum between Mende-
lian and complex traits [17]. Genetic testing comprised compo-
nents of the somatotropic axis, constituents of the IGF signaling
system and factors involved in cellular proliferation, which are
described or suggested to provoke syndromic or nonsyndromic
dwarfism phenotypes. As a major finding two compound
heterozygous nonsense mutations within the PCNT gene were
identified (p.[Arg585X];[Glu1774X]), which are suggested to
cause the patient’s phenotype. As a consequence, the diagnosis
was specified as MOPD II. The mutation
[(c.1753C.T(p.Arg585X)], inherited by the father, was already
described by Willems et al. [15]. The second mutation, inherited
by the mother, [(c.5320G.T (p.Glu1774X)] is a novel defect to
our knowledge. Both mutations lead to premature stop codons like
in other patients with MOPD II [3,15].
The PCNT gene encodes the centrosome protein pericentrin
which organizes the mitotic spindle for segregation of the
chromosomes during cell division and influences the cell cycle
progression. Rauch et al suggested that mitotic centrosome
dysfunction results in loss of cellularity, cell deaths and growth
restriction [3]. Thus pericentrin mutations can be expected to
cause disturbances in cell division and finally in growth of the body
and brain. MOPD II is a rare syndrome of extreme intrauterine
and postnatal growth retardation, microcephaly, resistance to
growth hormone, severe insulin resistance, bone and dental
dysplasia. Although most newborns born small for gestational
age show spontaneous catch-up growth within two to four years of
life, this does not happen in MOPD II. In addition, MOPD II
patients appear to have a resistance to growth hormone. Huang-
Doran et al described two patients in whom growth hormone
therapy was stopped because of inefficacy [12]. Our patient did
not show any catch-up growth during growth hormone therapy
though the dose was titrated to 69 ug/kg/day and IGF 1 increased
into the upper normal range.
Defects in pericentrin are associated with severe insulin
resistance and diabetes mellitus [12]. 17 out of 21 patients had
insulin resistance proven by elevated fasting insulin concentrations
and 10 out of 21 patients had early onset diabetes mellitus (mean
age 15 years with a range of 5 to 28). All patients without insulin
resistance were younger than four years. As an exception of the
rule glucose tolerance was still normal in our patient at the age of
7.1 years.
In spite of microcephaly brain development appears to be
grossly normal and most patients are said to have mild mental
retardation [3,15]. However, results of standardized examinations
are lacking in the literature. In our patient cognitive development
was more reduced than expected from a clinical point of view.
Figure 4. Proliferation of patient’s and wild type fibroblasts. Proliferation of patient’s fibroblasts (grey bars) and wild type fibroblasts (black
bars) as measured with WST-1 reagent assay. Cells were cultured for 24 h and 48 h in normal culture medium (NM), serum free medium (SFM), serum
free medium supplemented with 13 nM (100 ng/ml) IGF1 (SFM+IGF1). Then WST-1 reagent was added and absorbance was measured. Data were
normalized to the absorbance value obtained for wild type fibroblasts cultured in SFM for 24 h. Proliferation was significantly measurable in wild type
fibroblasts in NM, SFM, SFM+IGF1 between 24 h and 48 h. In contrast, there was no significant increase between 24 h and 48 h found in patient
fibroblasts cultured in NM, SFM, SFM+IGF1. Results were calculated from more than three independent experiments as mean of the relative
absorbance with 6 SEM.
doi:10.1371/journal.pone.0038220.g004
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like episodes and intracranial hemorrhages secondary to moya-
moya disease like cerebrovascular anomalies and aneurysms.
A review and natural history study by Hall et al. [18]
documented cerebral aneurysms or moyamoya angiopathy in 11
of 58 (19%) patients, leading to at least four deaths. A clinical
report and review by Brancati et al. [19] documented that 15 of 63
(24%) patients were found to have cerebral aneurysms or
moyamoya disease. 25 patients with the diagnosis of MOPD II
were followed by an Institutional Review Board (IRB) [20]. In this
registry a higher number of 52% (13 of 25) have been found to
have cerebral neurovascular abnormalities including moyamoya
angiopathy and/or intracranial aneurysms. The increased inci-
dence of cerebrovascular disease in this cohort might be based
upon the used MRI/MRA screening which detected abnormalities
also in asymptomatic individuals. Observed cerebral vascular
anomalies include moyamoya disease or multiple aneurysms.
There is only one report of a patient with both moyamoya disease
and multiple aneurysms by Waldron et al. [21]. Patients with
moyamoya disease show an earlier age at onset of these
complications compared to the group with intracranial aneurysms.
Although this latter subset of subjects had worse prognosis [22,23].
The occurrence of cerebral vascular anomalies already at an early
age highlights the importance of a timely neuroimaging in the
clinical management of these patients.
In some patients moyamoya disease was associated with cutis
marmorata [19,24], but not in our patient. It remains unclear how
the underlying genetic change leads to moyamoya angiopathy. We
agree that screening for moyamoya disease at the time of MOPD
II diagnosis and at least every 12–18 months, as suggested by the
IRB, should be performed to identify and treat progressive and life
threating cerebrovascular disease. If diagnosed early enough, re-
vascularization and aneurysm treatment in skilled hands can be
performed safely and might prevent or minimize long-term
sequelae in this population like in our patient so far.
Several mutations in the IGF1R have been reported to result in
common phenotypic features like IUGR, stunted postnatal growth
development, and microcephaly [4–11,25]. Generally, growth
retardation due to heterozygous IGF1R mutations has been
observed to occur in the borderline range (around -2 SDS) but can
exceed these limits down to nearly -6 SDS if non-genetic factors or
the genetic background are unfavorable [8,9]. Growth deficit may
even worsen if both IGF1R alleles are affected resulting in height
of -7.3 SDS at the age of 3 years [25]. Moreover, complete
receptor loss due to targeted disruption of the Igf1r gene in mice
leads to severely growth retarded offspring showing a birth length
of 45% compared to wild type littermates [26]. Although, in our
patient the profound growth deficit certainly is caused by the
aberrant pericentrin genes/proteins, such findings suggest that
dwarfism-like phenotypes can also be provoked by IGF1R
mutations under specific, adverse genetic or environmental
conditions. Moreover, the impact of co-occurring variants in
additional gene/s either residing on the same or unrelated growth
regulating pathways has not yet been described for the IGF1R.
Initial genetic analysis revealed a novel heterozygous p.L1361R
mutation within the IGF1R. Although this non-conservative
amino acid substitution affects a highly phylogenetically conserved
residue at the very COOH-terminal end of the IGF1R there is a
remarkable lack of co-segregation of the mutation with the growth
retarded phenotype within the family. Moreover, IGF1 receptor
mutations basically manifest as hormone resistance characterized
by normal or elevated IGF1 serum concentrations. In contrast, the
index patient displayed low-normal to decreased IGF1 levels at
several occasions before GH therapy. Although the decrease might
indicate some undefined additional IGF deficiency, sequencing of
the IGF1 gene as well as pituitary function tests and IGF1 response
during GH therapy were normal. It appears likely, that reduced
IGF1 levels might rather be a reflection of severe IUGR without
catch-up growth and low BMI [27]. Noteworthy, the endocrine
state in patients with PCNT mutations has not been evaluated
systematically, but IGF1 levels in Seckel and MOPD II patients
have been reported occasionally to be normal [28,29], elevated
[30,31] or low [28,30,32].
To elucidate the impact of the p.L1361R mutation and because
the function of the COOH-terminal tail of the IGF1R is only
poorly defined and no human mutation in this receptor portion
has been identified so far [33] we performed comprehensive
functional analysis.
Our and other groups showed that IGF1R mutations led to
disturbances of receptor trafficking [7] and abrogation of the
IGF1R tyrosine kinase activity [10,11]. Investigations of cell
surface expression, cellular expression and IGF1 dependent
phosphorylation of the mutant IGF1R were found to be normal
as was the activation of major signaling molecules. Since activation
was not modified we then addressed the question whether the
interactions of the mutant IGF1R with downstream signaling
proteins known to associate with the COOH-terminal tail of the
receptor (GIPC, 14-3-3, PI3Kp85) are affected. We found an
unchanged interaction between the mutant IGF1 receptor and the
PI3Kp85 protein and a significantly although moderately
decreased association with 14-3-3ß. In addition, association of
the IRS1 positive control with the mutant IGF1R was slightly
enhanced. It is described in literature that mutations and deletion
of the carboxy-terminal tail of the IGF1 receptor result in a higher
affinity of the receptor to IRS1 [34]. Most interestingly, we
detected an approximately 50% decrease in interaction between
the mutant receptor and the GIPC protein. Interaction of GIPC
with the IGF1R was first established by Ligensa et al. using a yeast
two-hybrid approach and has been shown to act positively in IGF1
receptor signal transduction in Xenopus oocytes [16,35]. Increased
expression and activation of the IGF1R and its downstream
signaling targets are related to human cancers [36,37]. Muders et
al. showed that GIPC expression is increased in human cells of
pancreatic adenocarcinoma (PCA) and knockdown of GIPC
results in decreased proliferation of PCA cells [38,39]. It was
hypothesized that GIPC is important for IGF1R membrane
stabilization [40], IGF1R trafficking and prevention of IGF1R
degradation [41]. Following studies showed that GIPC is involved
in IGF1 induced proliferation of different cancer cell lines and
cancer cell survival [42]. However, seeking for a ‘second site’
mutation within the possibly epistatically interacting GIPC1 gene
was without finding. Therefore, we suggest that the impaired
interaction of GIPC and the mutant IGF1R might elicit subtle
physiological effects that are neither obviously associated with
human growth control nor easily detectable in the fibroblast assays
as performed in our investigations. Additional experiments should
be initiated to assess the physiological relevance of this altered
interaction.
Cell proliferation of patient fibroblasts was decreased compared
to wild type cells and IGF1 application was only in the short term
(24 h) able to ameliorate the deficit. Failure to stimulate cell
division in response to IGF1 is reminiscent of the absent success of
rhGH therapy in the patient that to a large part relies on the
stimulation of endogenous IGF1 expression and action. However,
care must be taken if deducing the in vivo situation from in vitro data
obtained from fibroblast studies. The identified compound
heterozygous PCNT mutations may provide a plausible explana-
tion for the observed reduced cell proliferation and therefore the
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link pericentrin mutations with the dramatically reduced body size
in mice and humans. In all models disruption of the multifunc-
tional scaffolding properties of pericentrin has been suggested to
result in a massive loss of cellularity due to centrosome dysfunction
[43].
In conclusion, although the assumption of a second-site
mutation led to the identification of the pericentrin mutations it
is unlikely that the IGF1R mutation contributes to the patient’s
phenotype. Clinical manifestation of the unaffected father as
carrier of the PCNT p.R585X loss-of-function mutation and the
p.L1361R IGF1R – if at all – hypomorphic mutation as well as
demonstration that the major signaling pathways induced by the
mutant IGF1R are largely unimpaired suggest that the compound
heterozygous PCNT mutations on its own represent the underlying
cause of the patient’s phenotype.
Nonetheless, the quest for the ‘second hit’ remains a promising
challenge in polygenical traits such as growth, specifically in light
of the high portion of growth retarded, IGF1 resistant children
with unknown etiology and the considerable number of unique or
rare – possibly hypomorphic – allelic variants in the IGF1R gene
(unpublished data from our laboratory).
Moreover, our comprehensive work underlines the importance
of investigation of the functional relevance of mutations found by
diagnostic screenings to assess their pathogenic impact and for a
better understanding of the differential clinical picture possibly
affecting subsequent therapy strategies. Molecular biological
verification of identified mutations should be considered and
careful integration with clinical and genetic data is required to
avoid missing so far unidentified causative mechanisms.
In summary, we have identified a severely growth retarded girl
carrying a non-conservative amino acid exchange in the COOH-
terminal tail of the IGF1R. The functional analysis of the IGF1R
mutation revealed that the mutation might have subtle effects on
IGF1R biology but is assumed not to be causally related to the
patient’s phenotype. We suggest that the PCNT mutations account
for the severe growth retardation and microcephaly due to severly
diminished cell proliferation.
Materials and Methods
All investigations were performed after approval of the Ethical
Committee of the Medical Faculty of the University of Leipzig
(project-no.: 234-2006, date of report: 16.02.2007) and written
informed consent of the patient’s parents for molecular analysis
and publication as well as written informed consent of the same
age boy’s parents for publication.
Genetic analysis and endocrine evaluation
All coding exons of the IGF1R (NM_000875.3), IGF1, growth
hormone (GH1), GH receptor (GHR), GH releasing hormone
(GHRH), and GHRH receptor (GHRHR) genes were amplified by
PCR from peripheral blood DNA. Screening for sequence
aberrations was performed by temperature modulated heterodu-
plex HPLC on a reverse-phase column using the WAVE-System
(Transgenomics, Crewe, UK). PCR products displaying aberrant
chromatograms were further analyzed by direct sequencing.
Additional re-sequencing analyses [insulin receptor (INSR), insulin
receptor substrate 1 (IRS1), GAIP C-terminus-interacting protein 1
(synectin, GIPC1), signal-transducer and activator of transcription
5B (STAT5B), pericentrin (PCNT; NM_006031.5)] were per-
formed by direct sequencing of exon-specific genomic PCR
fragments without dHPLC pre-screening. Primer sequences can
be obtained upon request. DNA tests to investigate uniparental
disomies were performed by PCR using locus specific microsat-
ellite markers. IGF1 levels were measured with Immulite 2000
(analytical sensitivity 20 ng/ml, intraassay CV 3.05%, interassay
CV 6.16%; Siemens, Munich, Germany). All other hormones
were analyzed at the hospital laboratories of Leipzig and Augsburg
by certified standard techniques.
Plasmid construction
IGF1R wild type cDNA was kindly provided by Dr. R.
Furlanetto (previously Medical University of South Carolina, SC)
and cloned into a pBSK+ plasmid. The IGF1R mutation was
introduced into the wild type cDNA by PCR using a mutated
adapter primer. The IGF1R-L1361R PCR fragment was ligated
into the pBSK+IGF1R plasmid and thereafter subcloned either
into the expression plasmid pcDNA3-IGF1R (pcDNA3-IGF1R-
L1361R) or into pLexA-IGF1R-C for yeast-two-hybrid assays
(pLexA-IGF1R-L1361R). The latter one encodes for a fusion
protein of the intracellular domain of the IGF1R (IGF1R-C) and a
LexA DNA binding domain.
The construction of ‘‘kinase-dead’’ mutant pcDNA3-
IGF1R(K1003A) was performed as previously described [10].
Construction of plasmids encoding for fusion proteins comprising
the transcription activation domain B42 (B42-AD) and IRS1,
p85PI3-K, or 14-3-3b was previously described [44]. The human
GIPC cDNA (GIPC1, synectin, MIM 605072) was cloned by RT-
PCR using RNA isolated from the MCF-7 breast cancer cell line
as template. Detailed description of all cloning procedures can be
provided upon request.
Cell culture and transient transfection
Patient fibroblasts were cultured from a forearm skin biopsy.
Wild type human control fibroblasts of age- and sex-matched
donors were purchased from the American Type Culture
Collection (LGC Standards, Wesel, Germany). Human fibroblasts
and Igf1r deficient (R
2) fibroblasts were cultured under standart
conditions.
For transient transfection R
2 cells were grown to confluence
and transfected with empty pcDNA3.1+, wild type pcDNA3-
IGF1R or pcDNA3-IGF1-L1361R using Lipofectamine2000
(Invitrogen, Karlsruhe, Germany) as described in the manufac-
turer’s manual.
Flow cytometry
IGF1R cell surface expression of patient and control fibroblasts
were analyzed as previously described [7] using flow cytometry
(Epics XL, Beckman Coulter, Miami, FL). Fibroblasts were stained
with phycoerythrin-conjugated human IGF1R mAb (R&D Sys-
tems, Minneapolis, MN). An appropriate isotype control (R&D
Systems) was applied for gating.
IGF1 stimulated phosphorylation of the IGF1R
Expression of unphosphorylated and phosphorylated IGF1R
protein was determined in patient and wild type fibroblasts.
Therefore, the cells were seeded into 175 cm
2 flasks in culture
medium, kept in serum free medium containing 0.2% BSA
(Invitrogen) overnight and then stimulated with 13 nM (100 ng/
ml) IGF1 (Amersham Pharmacia Biotech, Uppsala, Sweden) for
15 min at 37uC.
R
2 cells were used for measuring time and dose dependent
IGF1 induced phosphorylation of IGF1R, Akt and Mapk/Erk.
24 hours after transfection cells were starved overnight in serum
free medium containing 0.2% BSA (Invitrogen). To detect dose-
dependent activation of the IGF1R, cells were incubated with
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10, 100 nM) for 15 min at 37uC. To detect time-dependent
activation of the IGF1R, cells were incubated with 10 nM IGF1 in
serum free medium for 0, 1, 1.5, 2, 5, 15, 30 minutes. Cell lysis
was performed as previously described [7] and lysates were used
for immunoblotting.
Immunoblotting
Expression and ligand-induced phosphorylation of IGF1R, Akt,
and Mapk/Erk were measured by immunoblotting using specific
antibodies. Preparation of whole-cell lysates and subsequent







Erk1/2 #9101, anti-Akt #9272, anti-p44/42 Mapk/Erk1/2
#9102 (New England Biolabs, Frankfurt/Main, Germany), anti-
IGF1Ra #N-20 (Santa Cruz Biotechnology, Heidelberg, Ger-
many) and anti-ß-actin monoclonal antibody (Sigma-Aldrich,
Schnelldorf, Germany) were applied as primary antibodies.
Horseradish peroxidase conjugated goat anti-rabbit antibody
(Thermo Fisher Scientific, Bonn, Germany) and goat anti-mouse
antibody (Dako, Hamburg, Germany) were used as secondary
antibodies.
Yeast-two-hybrid assays
EGY48/LacZ yeast strain was used for co-transformation with
pLexA and pB42 constructs applying polyethylene glycol and
lithium acetate. All yeast incubations were performed at 30uC.
Colony-lift filter assays and liquid culture assays using OPNG (o-
nitrophenyl b-D-galactopyranoside; Sigma-Aldrich) were per-
formed according to Clontech’s Matchmaker protocol (Clontech
BD Biosciences, Palo Alto, CA). Absorption measurements for
liquid culture assays were performed at 420 nm and b-galactosi-
dase units were calculated according to the Miller formula.
Proliferation assay
Proliferative capacity of the patient’s and wild type fibroblasts
was assessed using Cell Proliferation Reagent WST-1 (Roche
Diagnostics, Mannheim, Germany). The cells were allowed to
grow for 24 h or 48 h in culture medium, serum free culture
medium or serum free culture medium supplemented with 13 nM
(100 ng/ml) IGF1. WST-1 reagent was added followed by
incubation at 37uC for 2 h. Absorption was measured at 440 nm.
Supporting Information
Figure S1 Clinical course of the IGF1 serum levels
before and under GH treatment. In the course of GH
therapy IGF1 serum levels rose steadily from less than -1.9 SDS at
several occasions before GH treatment to 1.1 SDS under GH
treatment. Black bar assigns period of rhGH therapy.
(TIF)
Figure S2 Protein and cell surface expression of IGF1R
in wild type and patient’s fibroblasts. A, Protein expression
and autophosphorylation of IGF1R of wild type fibroblasts
(IGF1R-WT), patient’s fibroblasts (IGF1R-L1361R) and parental
fibroblasts after stimulation with 13 nM (100 ng/ml) IGF1 for
15 minutes was assessed by immunoblotting. Blots were incubated
with specific antibodies against phosphorylated IGF1R b-subunit
(P-IGF1R), stripped and subsequently incubated with specific
antibodies against IGF1R a-subunit (IGF1R). Immunoblots shown
are representative for three independent experiments. B, Expres-
sion of the IGF1R on cell surface of wild type and patient’s
fibroblasts. Cells were stained with phycoerythrin (PE) labelled
antibodies and analyzed by flow cytometry. Black curve marks
cells labeled with isotype control PE antibody, white curve marks
cells labeled with human anti-IGF1R-PE antibody. Percentages of
IGF1R PE positive cells are indicated. The mean fluorescence
intensity of the IGF1R-phycoerythrin-antibody positive cells
normalized to wild type fibroblasts represent the amount of cell
surface IGF1R. Results are shown as means 6 SEM calculated
from more than three independent experiments.
(TIF)
Acknowledgments
We thank Dr. Christian Thiel from the Institute of Human Genetics in
Erlangen for identifying the compound heterozygous PCNT mutation of
the patient. In addition we gratefully thank the patient’s family for their
great and persistent cooperation.
Author Contributions
Conceived and designed the experiments: EM J. Klammt WK RP SL.
Performed the experiments: EM SL. Analyzed the data: EM J. Klammt.
Contributed reagents/materials/analysis tools: EM J. Klammt DF WK RP
J. Kratzsch SL TW TK. Wrote the paper: EM J. Klammt WK RP DF DD
PHH.
References
1. Majewski F, Goecke TO (1998) Microcephalic osteodysplastic primordial
dwarfism type II: report of three cases and review. Am J Med Genet 80: 25–31.
2. Majewski F, Ranke M, Schinzel A (1982) Studies of microcephalic primordial
dwarfism II: the osteodysplastic type II of primordial dwarfism. Am J Med Genet
12: 23–35.
3. Rauch A, Thiel CT, Schindler D, Wick U, Crow YJ, et al. (2008) Mutations in
the pericentrin (PCNT) gene cause primordial dwarfism. Science 319: 816–819.
4. Fang P, Schwartz ID, Johnson BD, Derr MA, Roberts CT, et al. (2009) Familial
short stature caused by haploinsufficiency of the insulin-like growth factor i
receptor due to nonsense-mediated messenger ribonucleic acid decay. J Clin
Endocrinol Metab 94: 1740–1747.
5. Raile K, Klammt J, Schneider A, Keller A, Laue S, et al. (2006) Clinical and
functional characteristics of the human Arg59Ter insulin-like growth factor i
receptor (IGF1R) mutation: implications for a gene dosage effect of the human
IGF1R. J Clin Endocrinol Metab 91: 2264–2271.
6. Kawashima Y, Kanzaki S, Yang F, Kinoshita T, Hanaki K, et al. (2005)
Mutation at cleavage site of insulin-like growth factor receptor in a short-stature
child born with intrauterine growth retardation. J Clin Endocrinol Metab 90:
4679–4687.
7. Wallborn T, Wuller S, Klammt J, Kruis T, Kratzsch J, et al. (2010) A
heterozygous mutation of the insulin-like growth factor-I receptor causes
retention of the nascent protein in the endoplasmic reticulum and results in
intrauterine and postnatal growth retardation. J Clin Endocrinol Metab 95:
2316–2324.
8. Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, et al. (2003)
IGF-I receptor mutations resulting in intrauterine and postnatal growth
retardation. N Engl J Med 349: 2211–2222.
9. Inagaki K, Tiulpakov A, Rubtsov P, Sverdlova P, Peterkova V, et al. (2007) A
familial insulin-like growth factor-I receptor mutant leads to short stature:
clinical and biochemical characterization. J Clin Endocrinol Metab 92:
1542–1548.
10. Kruis T, Klammt J, Galli-Tsinopoulou A, Wallborn T, Schlicke M, et al. (2010)
Heterozygous mutation within a kinase-conserved motif of the insulin-like
growth factor I receptor causes intrauterine and postnatal growth retardation.
J Clin Endocrinol Metab 95: 1137–1142.
11. Walenkamp MJ, van der Kamp HJ, Pereira AM, Kant SG, van
Duyvenvoorde HA, et al. (2006) A variable degree of intrauterine and postnatal
growth retardation in a family with a missense mutation in the insulin-like
growth factor I receptor. J Clin Endocrinol Metab 91: 3062–3070.
12. Huang-Doran I, Bicknell LS, Finucane FM, Rocha N, Porter KM, et al. (2011)
Genetic defects in human pericentrin are associated with severe insulin
resistance and diabetes. Diabetes 60: 925–935.
13. Kotzot D (2004) Maternal uniparental disomy 14 dissection of the phenotype
with respect to rare autosomal recessively inherited traits, trisomy mosaicism,
and genomic imprinting. Ann Genet 47: 251–260.
14. Kotzot D, Utermann G (2005) Uniparental disomy (UPD) other than 15:
phenotypes and bibliography updated. Am J Med Genet A 136: 287–305.
Analysis of a Patient with PCNT and IGF1R Mutation
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e3822015. Willems M, Genevieve D, Borck G, Baumann C, Baujat G, et al. (2010)
Molecular analysis of pericentrin gene (PCNT) in a series of 24 Seckel/
microcephalic osteodysplastic primordial dwarfism type II (MOPD II) families.
J Med Genet 47: 797–802.
16. Ligensa T, Krauss S, Demuth D, Schumacher R, Camonis J, et al. (2001) A
PDZ domain protein interacts with the C-terminal tail of the insulin-like growth
factor-1 receptor but not with the insulin receptor. J Biol Chem 276:
33419–33427.
17. Badano JL, Katsanis N (2002) Beyond Mendel: an evolving view of human
genetic disease transmission. Nat Rev Genet 3: 779–789.
18. Hall JG, Flora C, Scott CI, Jr., Pauli RM, Tanaka KI (2004) Majewski
osteodysplastic primordial dwarfism type II (MOPD II): natural history and
clinical findings. Am J Med Genet A 130A: 55–72.
19. Brancati F, Castori M, Mingarelli R, Dallapiccola B (2005) Majewski
osteodysplastic primordial dwarfism type II (MOPD II) complicated by stroke:
clinical report and review of cerebral vascular anomalies. Am J Med Genet A
139: 212–215.
20. Bober MB, Khan N, Kaplan J, Lewis K, Feinstein JA, et al. (2010) Majewski
osteodysplastic primordial dwarfism type II (MOPD II): expanding the vascular
phenotype. Am J Med Genet A 152A: 960–965.
21. Waldron JS, Hetts SW, Armstrong-Wells J, Dowd CF, Fullerton HJ, et al. (2009)
Multiple intracranial aneurysms and moyamoya disease associated with
microcephalic osteodysplastic primordial dwarfism type II: surgical consider-
ations. J Neurosurg Pediatr 4: 439–444.
22. Di Bartolomeo R, Polidori G, Piastra M, Viola L, Zampino G, et al. (2003)
Malignant hypertension and cerebral haemorrhage in Seckel syndrome.
Eur J Pediatr 162: 860–862.
23. Sorof JM, Dow-Smith C, Moore PJ (1999) Severe hypertensive sequelae in a
child with Seckel syndrome (bird-like dwarfism). Pediatr Nephrol 13: 343–346.
24. Kannu P, Kelly P, Aftimos S (2004) Microcephalic osteodysplastic primordial
dwarfism type II: a child with cafe au lait lesions, cutis marmorata, and
moyamoya disease. Am J Med Genet A 128A: 98–100.
25. Fang P, Cho YH, Derr MA, Rosenfeld RG, Hwa V, et al. (2012) Severe short
stature caused by novel compound heterozygous mutations of the insulin-like
growth factor 1 receptor (IGF1R). J Clin Endocrinol Metab 97: E243–E247.
26. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A (1993) Mice carrying
null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type
1 IGF receptor (Igf1r). Cell 75: 59–72.
27. Juul A (2003) Serum levels of insulin-like growth factor I and its binding proteins
in health and disease. Growth Horm IGF Res 13: 113–170.
28. Faivre L, Le Merrer M, Lyonnet S, Plauchu H, Dagoneau N, et al. (2002)
Clinical and genetic heterogeneity of Seckel syndrome. Am J Med Genet 112:
379–383.
29. Kjaer I, Hansen N, Becktor KB, Birkebaek N, Balslev T (2001) Craniofacial
morphology, dentition, and skeletal maturity in four siblings with Seckel
syndrome. Cleft Palate Craniofac J 38: 645–651.
30. Ducos B, Cabrol S, Houang M, Perin L, Holzenberger M, et al. (2001) IGF type
1 receptor ligand binding characteristics are altered in a subgroup of children
with intrauterine growth retardation. J Clin Endocrinol Metab 86: 5516–5524.
31. Schmidt A, Chakravarty A, Brommer E, Fenne BD, Siebler T, et al. (2002)
Growth failure in a child showing characteristics of Seckel syndrome: possible
effects of IGF-I and endogenous IGFBP-3. Clin Endocrinol (Oxf) 57: 293–299.
32. Dumitrescu C, Procopiuc C, Dumitrascu A (2010) A Case of Severe Growth
Retardation, Probably Seckel Syndrome. Acta Endocrinologica-Bucharest 6:
361–369.
33. Klammt J, Kiess W, Pfaffle R (2011) IGF1R mutations as cause of SGA. Best
Pract Res Clin Endocrinol Metab 25: 191–206.
34. Tartare-Deckert S, Sawka-Verhelle D, Murdaca J, Van Obberghen E (1995)
Evidence for a differential interaction of SHC and the insulin receptor substrate-
1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-
hybrid system. J Biol Chem 270: 23456–23460.
35. Booth RA, Cummings C, Tiberi M, Liu XJ (2002) GIPC participates in G
protein signaling downstream of insulin-like growth factor 1 receptor. J Biol
Chem 277: 6719–6725.
36. Larsson O, Girnita A, Girnita L (2007) Role of insulin-like growth factor 1
receptor signalling in cancer. Br J Cancer 96 Suppl: R2–R6.
37. LeRoith D, Werner H, Neuenschwander S, Kalebic T, Helman LJ (1995) The
role of the insulin-like growth factor-I receptor in cancer. Ann N Y Acad Sci
766: 402–408.
38. Muders MH, Dutta SK, Wang L, Lau JS, Bhattacharya R, et al. (2006)
Expression and regulatory role of GAIP-interacting protein GIPC in pancreatic
adenocarcinoma. Cancer Res 66: 10264–10268.
39. Muders MH, Vohra PK, Dutta SK, Wang E, Ikeda Y, et al. (2009) Targeting
GIPC/synectin in pancreatic cancer inhibits tumor growth. Clin Cancer Res 15:
4095–4103.
40. Lou X, Yano H, Lee F, Chao MV, Farquhar MG (2001) GIPC and GAIP form
a complex with TrkA: a putative link between G protein and receptor tyrosine
kinase pathways. Mol Biol Cell 12: 615–627.
41. Naccache SN, Hasson T, Horowitz A (2006) Binding of internalized receptors to
the PDZ domain of GIPC/synectin recruits myosin VI to endocytic vesicles.
Proc Natl Acad Sci U S A 103: 12735–12740.
42. Choi JS, Paek AR, Kim SY, You HJ (2010) GIPC mediates the generation of
reactive oxygen species and the regulation of cancer cell proliferation by insulin-
like growth factor-1/IGF-1R signaling. Cancer Lett 294: 254–263.
43. Delaval B, Doxsey SJ (2010) Pericentrin in cellular function and disease. J Cell
Biol 188: 181–190.
44. Klammt J, Garten A, Barnikol-Oettler A, Beck-Sickinger AG, Kiess W (2005)
Comparative analysis of the signaling capabilities of the insulin receptor-related
receptor. Biochem Biophys Res Commun 327: 557–564.
Analysis of a Patient with PCNT and IGF1R Mutation
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e38220